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SUMMARY 
 
Aims 
Blood flow generates wall shear stress (WSS) which alters endothelial cell (EC) function. 
Low WSS promotes vascular inflammation and atherosclerosis whereas high uniform 
WSS is protective. Ivabradine decreases heart rate leading to altered hemodynamics. 
Besides its cardio-protective effects, ivabradine protects arteries from inflammation and 
atherosclerosis via unknown mechanisms. We hypothesised that ivabradine protects 
arteries by increasing WSS to reduce vascular inflammation.  
 
Methods and Results 
Hypercholesterolemic mice were treated with ivabradine for 7 weeks in drinking water or 
remained untreated as a control. En face immunostaining demonstrated that treatment 
with ivabradine reduced the expression of pro-inflammatory VCAM-1 (p<0.01) and 
enhanced the expression of anti-inflammatory eNOS (p<0.01) at the inner curvature of 
the aorta. We concluded that ivabradine alters EC physiology indirectly via modulation of 
flow because treatment with ivabradine had no effect in ligated carotid arteries in vivo, 
aQGGLGQRW LQIOXHQFHWKHEDVDORU71)Į-induced expression of inflammatory (VCAM-1, 
MCP-1) or protective (eNOS, HMOX1, KLF2, KLF4) genes in cultured EC. We therefore 
considered whether ivabradine can alter WSS which is a regulator of EC inflammatory 
activation. Computational fluid dynamics demonstrated that ivabradine treatment 
reduced heart rate by 20% and enhanced WSS in the aorta.  
 
Conclusions  
Ivabradine treatment altered hemodynamics in the murine aorta by increasing the 
magnitude of shear stress. This was accompanied by induction of eNOS and 
suppression of VCAM-1, whereas ivabradine did not alter EC that could not respond to 
flow. Thus ivabradine protects arteries by altering local mechanical conditions to trigger 
an anti-inflammatory response. 
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INTRODUCTION 
Heart rate is an important risk factor and therapeutic target in cardiovascular disease1-6. 
Elevated heart rate was associated with poor cardiovascular outcome in patients with 
heart failure or acute myocardial infarction 1, 2. Correspondingly, interventions that 
lowered resting heart rate led to protection from experimental atherogenesis 5, 6 and 
reduced infarct size and mortality rates in patients with acute myocardial infarction3. A 
beneficial effect of heart rate reduction on coronary artery disease was also 
demonstrated in clinical trials using ivabradine. This compound decreases heart rate by 
inhibiting the If current in the sinus node, without affecting blood pressure or systolic 
ventricular function. Ivabradine treatment improved prognosis in patients with chronic 
heart failure7 and had anti-ischemic effects in patients with stable angina8. Moreover, 
ivabradine was associated with a reduction in coronary endpoints in coronary artery 
disease patients with left ventricular dysfunction and heart rate t70 bpm9. Despite this, a 
recent study found that ivabradine did not have beneficial effects in patients with stable 
coronary artery disease but without heart failure10, suggesting that its vasculoprotective 
effects may be restricted to patients with heart failure. The mechanism for the protective 
effects of ivabradine has been studied using animal models11-14. The administration of 
ivabradine reduced experimental atherosclerosis in hyperlipidaemic murine13 and rabbit 
models 14. However, molecular targets of ivabradine have not been identified in vascular 
cells and the atheroprotective effects of ivabradine are not due to a lipid-lowering effect 
of ivabradine, since the drug had no effects on cholesterol levels11-13. Taken together, 
these experiments suggest that a direct effect of ivabradine on vessels is unlikely, and 
suggest that reduction of heart rate may be a primary mechanism of action of the drug. 
 
Arteries are exposed to mechanical forces including mechanical wall stress (tangential, 
longitudinal or circumferential) and blood-flow induced wall shear stress (WSS) that play 
important roles in vascular homeostasis and disease. Indeed, although atherosclerosis is 
associated with systemic risk factors, such as hypercholesterolemia, it develops 
preferentially at branches and bends of the arterial tree that are exposed to complex 
patterns of blood flow15. Computational fluid dynamic (CFD) studies have demonstrated 
that the magnitude of WSS (time-averaged WSS (TAWSS) over the cardiac cycle) is 
lower at atherosclerosis-prone sites exposed to complex flow compared to regions that 
are protected16,17. Low WSS promotes atherosclerosis by inducing endothelial 
expression of inflammatory molecules (e.g. VCAM-1) that promote lesions18-20, whereas 
high unidirectional WSS induces anti-inflammatory genes such as eNOS21. Although 
ivabradine is known to increase stroke volume and coronary perfusion22, its effects on 
WSS have not been studied. Here we tested the hypothesis that ivabradine protects 
arteries by enhancing WSS which reduces inflammatory activation of arterial EC. 
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MATERIAL AND METHODS 
Animals, surgery, ivabradine treatment and diet 
All experiments conform to the guidelines laid out in the UK Animals Scientific 
Procedures Act (1986) and to the guidelines from Directive 2010/63/EU of the European 
Parliament on the protection of animals used for scientific purposes, and were performed 
under a project license from the UK Home Office. LDLR-/- (low-density lipoprotein 
receptor±deficient) mice on a C57BL/6 genetic background were obtained commercially 
from Jackson laboratories and then bred in-house. All mice used in this study were male. 
Mice were housed under specific-pathogen free conditions. Where indicated, mice of 8 
weeks of age were anaesthetized using a mixture of ketamine, xylazine and atropine 
prior to surgical exposure of the carotid arteries. The right carotid artery was ligated 
using cotton thread immediately proximal to the carotid bifurcation. Mice were allowed to 
recover for 1 week prior to experimentation. Some animals were treated with ivabradine 
either by i.v. injection (5 mg/kg) or in drinking water ad libitum (162 mg/L for 1 or 7 
weeks). Alternatively, mice remained untreated as a control. Where indicated, normal 
chow diet was replaced at 10 weeks of age with Diet W; a cholate-free high-fat Western-
type diet (Arieblok Diet W, 4021.06; Woerden, Netherlands) for 6 weeks. The Diet W 
(high-fat diet) consisted of (w/w) Cocoa butter (15%), cholesterol (0.25%), sucrose 
(40.5%), cornstarch (10%), corn oil (1%), cellulose (5.95%), casein (20%), 50% choline 
chloride (2%), methionine (0.2%) and mineral mixture (5.1%), total fat content (16%).  
 
En face staining. Animals were killed using pentobarbital (800 mg/kg by intraperitoneal 
injection). Endothelial expression of VCAM-1 or eNOS was determined by en face 
staining of the murine aorta as described18,20. Briefly, aortae were perfusion fixed and 
isolated prior to permeabilisation using 0.5% Triton X-100 (Sigma-Aldrich), and blocking 
with 20% goat serum for 2 h at room temperature. After washing with phosphate-
buffered saline, the tissue was incubated with anti-VCAM-1 (EPR505; Novus Biologicals 
UK) or anti-eNOS (BD Bioscences) primary antibodies overnight at 4 °C. The tissue was 
then washed with PBS and incubated with goat anti-rabbit IgG antibody conjugated to 
AlexaFluor-568 (A11036; Invitrogen) for 2-3 h at room temperature followed by 
incubation with AlexFlour-488 labelled anti-CD31 antibody (102514; BioLegend) for 72-
120 h at 4°C. The tissue was incubated with TOPRO-3 to counterstain nuclei. To control 
for specific binding, tissues were incubated with irrelevant rabbit IgG antibodies and 
appropriate fluorescent secondary antibodies, or were incubated with secondary 
antibodies alone. The ascending aorta and arch were mounted and images of the EC 
monolayer were obtained using an inverted laser-scanning confocal microscopy (LSM 
510 Meta inverted; Zeiss, Oberkochen, Germany). Protected (outer curvature) and 
susceptible (inner curvature) regions of the aortic arch were located using anatomical 
landmarks as described20. The mean expression levels of VCAM-1 and eNOS were 
determined by pooling mean fluorescence values from multiple cells (> 50 cells per field 
of view).  
 
EC culture and exposure to shear stress. Human umbilical vein EC (HUVEC) were 
isolated using collagenase digestion and cultured. EC at passage 3-5 were cultured until 
confluent in 6 well plates and exposed to flow using an orbital shaking platform (PSU-
10i; Grant Instruments) housed inside a cell culture incubator23. The radius of orbit of the 
orbital shaker was 10 mm and the rotation rate was set to 210 rpm. This system 
generated low shear stress (approximately 5 dyn/cm2) with rapid variations in direction in 
the centre and high shear stress (approximately 15 dyn/cm2) with relatively uniform 
direction at the periphery23.  
 
Comparative real time PCR. The levels of transcripts were assessed using quantitative 
real time PCR (qRT-PCR) as described18,23 using gene-specific primers (Supplementary 
Table 1). Relative gene expression was calculated by comparing the number of thermal 
cycles that were necessary to generate threshold amounts of product. Fold changes 
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were FDOFXODWHGXVLQJWKHǻǻ&WPHWKRG 
 
Vascular geometry and heart rate measurements 
Heart rate and blood pressure were measured in conscious, restrained LDLR-/- mice 
using a commercial automated system Visitech Systems, Apex, NC. In order to 
familiarize mice to this procedure, daily measurements were carried out for two weeks 
prior to experimentation. Mean blood pressure and heart rate values were generated by 
pooling data from 20 measurements. 
 
CT angiography was carried out as described (Inveon, Siemens)24. Electrocardiogram 
gating was used to minimize movement artefacts caused by the movement of the heart 
and of the vessel during the cardiac cycle. Thus all images were acquired at the same 
time point of the cycle, the end of diastole, to avoid scanning during the dilation of the 
aorta during systole. Transthoracic echocardiography was carried out using a 
commercial system (Vevo 770® with a RMV707B scan head, Visual Sonics, Toronto, 
Canada) as described25. Briefly mice were anaesthetised with isoflurane via oxygen 
before being placed supine on a heated platform and covered to minimise heat loss. 
Maintenance Isoflurane (0.5-1.5%) with oxygen was delivered via a nose cone. 
Following depilation, Doppler pulse wave velocities were captured from peak flow in the 
ascending aorta. Data were averaged from 3-5 measurements per mouse. 
 
Computational fluid dynamics (CFD) 
The triangulated lumen surface was imported into ANSYS ICEM-CFD to generate a high 
quality hybrid tetrahedral mesh with prismatic boundary layer. The use of a prismatic 
layer of 4 cells allows for accurate representation of the WSS using a low overall cell 
count. Preliminary grid sensitivity studies using grid sizes from 80,000 to 500,000 cells 
showed that the results for WSS were grid insensitive within 2% for a grid size of 
approximately 200,000 cells while allowing for low simulation times of approximately 8 h 
on 2 cores of a 2.5GHz Intel i7 processor. 
 
The unsteady Navier-Stokes equations were solved numerically using the finite volume 
method (FVM) in ANSYS FLUENT 14.5. The vessel geometry was assumed to be rigid. 
Blood was modelled as a Newtonian fluid with a dynamic viscosity of  (4 
cP) and a density of . Using a typical maximum flow speed at the aortic root 
 and the hydraulic diameter of , the maximum Reynolds number is 
 
The flow was therefore modelled as laminar.  
 
The aortic root cross section was extruded by 10 diameters to allow for development of 
the flow and prescription of a Dirichlet inlet boundary condition for the normal velocity as 
a plug profile at the extruded section. The time dependent mean velocity was digitized 
from the US Doppler images and a 3rd order Bezier approximation26 was used to 
generate a second-order-smooth mean velocity curve. 
 
At the exit of the aorta descendens and the branches a Neumann outlet boundary 
condition was used with a flow split of 70, 16, 8 and 6 percent for aorta descendens, 
innominate, common carotid and subclavian, respectively.  
 
Numerical solutions were obtained using cell based higher with second order pressure, 
quadratic upwind momentum and second order implicit time discretization. Time step 
size was chosen as 1/400th or 1/600th of the cycle time for the control and ivabradine 
cases, respectively, maximum Courant numbers were below 8. In addition to the solution 
vector, three dimensional WSS data for the aorta and the defined ROI at the outer and 
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inner curvature were area-averaged during run time. From the time-dependent WSS, the 
time-averaged WSS at the wall was calculated: 
 
 
 
 
Statistics   Differences between samples were analysed using an unpaired or paired 
6WXGHQW¶VW-test, one-ZD\$129$ZLWK%RQIHUURQL¶VDGMXVWPHQWRUWZR-way ANOVA with 
SiGDN¶VPXOWLSOHFRPSDULVRQWHVW 
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RESULTS 
Ivabradine reduced inflammation of arterial EC.  
We hypothesized that ivabradine protects rodent arteries by reducing inflammatory 
activation of EC. This was assessed using LDLR-/- mice exposed to a high fat diet for 6 
weeks, a regime that is known to generate hypercholesterolemia and inflammatory 
activation of aortic EC27. In the first instance, we investigated whether oral ivabradine 
can reduce heart rate in LDLR-/- mice. Male LDLR-/- mice were exposed to ivabradine in 
drinking water for 7 weeks or were exposed to untreated water as a control (Fig. 1A). 
The average consumption of water in ivabradine-treated and control groups was similar 
(4.85 versus 5.27 ml/day/animal, respectively) and it was calculated that treated animals 
consumed an average of 27 mg/kg ivabradine daily. Pressure cuff measurements 
revealed that treatment with ivabradine reduced heart rate by approximately 20% but did 
not influence systolic or diastolic blood pressure (Fig. 1B). Thus although ivabradine was 
administered to LDLR-/- mice at doses significantly greater than those used clinically 
(0.25-0.33 mg/kg/day) it caused a reduction in heart rate that was proportional to that 
observed in ivabradine-treated patients7-9. 
 
We examined whether reduced heart rate in ivabradine-treated mice was associated 
with an altered inflammatory profile using en face staining to quantify endothelial 
expression of molecules with inflammatory (VCAM-1) or anti-inflammatory (eNOS) 
function. In untreated mice, VCAM-1 expression in EC was significantly higher at the 
inner compared to the outer curvature (Fig. 2, left panels), whereas eNOS expression 
was comparable at the inner and outer curvature (Fig. 3, left panels). Treatment with 
ivabradine significantly reduced VCAM-1 expression and simultaneously increased 
eNOS expression at both the inner and outer curvatures demonstrating that ivabradine 
reduced inflammation in aortic EC (Figs. 2 and 3, compare left and right panels). Thus 
we conclude that ivabradine exerts anti-inflammatory effects in the murine aorta by 
inducing eNOS and by suppressing VCAM-1. 
 
Ivabradine did not have direct pharmacological effects on EC.  
We wished to know whether ivabradine reduces vascular inflammation directly by 
pharmacological modification of EC or whether it acts indirectly by altering heart rate and 
hemodynamics. To address this, we exposed cultured HUVEC to ivabradine and 
determined the expression of inflammatory and anti-inflammatory genes. HUVEC were 
cultured under shear stress for 72 h using an orbiting 6-well plate system that generates 
low mean shear stress at the centre, and high mean shear stress at the periphery. They 
were simultaneously exposed to ivabradine at concentrations that mimic those detected 
in plasma in ivabradine-treated individuals (25-50 ng/ml)28. Some cultures were 
subsequently treated with the proinflammatory cytokine TNFD to determine the effect of 
ivabradine on inflammatory responsiveness. qRT-PCR revealed that the expression of 
the inflammatory effector molecules VCAM-1 and MCP-1 was enhanced in EC exposed 
to low compared to high WSS, and that anti-inflammatory eNOS, HMOX1, KLF2 and 
KLF4 displayed the opposite pattern (Fig. 4, compare treatments 1 and 7). The 
application of TNFD enhanced the expression of VCAM-1, MCP-1 and HMOX-1 but 
reduced the expression of KLF2, KLF4 (under low WSS only) and eNOS (under high 
WSS only) (Fig. 4, compare treatments 1, 4 and 7, 10). Notably, treatment of EC with 
ivabradine had no effect on the expression of VCAM-1, MCP-1, KLF2, KLF4, HMOX-1 or 
eNOS under high WSS (compare treatments 1, 2, 3) or low WSS (compare 7, 8, 9), and 
did not alter their modulation by TNFD (compare 4, 5, 6 and 10, 11, 12). Thus we 
conclude that ivabradine does not alter EC inflammatory or protective responses directly. 
 
The potential ability of ivabradine to alter EC directly was also studied by ligating carotid 
arteries in LDLR-/- mice so that EC were exposed to static conditions. After carotid artery 
ligation, mice were exposed to ivabradine for 7 weeks (in drinking water as above) or to 
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untreated water as a control. En face staining revealed that eNOS expression was 
negligible in ligated arteries of control- or ivabradine-treated animals (Supplementary 
Figure). This observation is consistent with previous reports that eNOS is shear-
sensitive21 and indicates that ivabradine does not induce eNOS expression in EC directly 
via a pharmacological effect. In summary, ivabradine had anti-inflammatory effects in the 
aorta which is exposed to flow but did not influence EC in cultured EC or cuffed arteries 
exposed to static conditions. Thus we conclude that ivabradine does not alter EC 
activation directly. Instead, our data are consistent with the hypothesis that ivabradine 
reduces inflammation of arteries by altering hemodynamics.  
 
Heart rate reduction by ivabradine increased average wall shear stress. 
Next, we tested the hypothesis that ivabradine protects atheroprone sites by increasing 
the magnitude of WSS. This was studied by CFD, which relies on accurate 
measurement of vascular geometries and blood flow velocities. WSS is sensitive to 
changes in vascular diameter since it is inversely proportional to the vessel radius 
cubed. Because of this we examined whether treatment of mice with ivabradine altered 
the geometry of the aorta. MRI revealed that exposure of mice to ivabradine for 7 weeks 
(in drinking water as above) did not influence the diameter of the aortic arch (1.7 +/- 0.04 
mm versus 1.76 +/- 0.06 mm respectively, p>0.1; measured between the 
brachiocephalic and left common carotid artery). We next assessed the effects of 
ivabradine on blood flow velocities which were measured by transthoracic 
echocardiography. Since mice were anesthetised for this procedure, ivabradine was 
administered by intra-venous injection to ensure high precision in dose and timing. We 
wished to achieve a heart rate reduction of approximately 20% since this is similar to the 
reduction observed in mice used for assessment of inflammation (Fig. 1B). Using varying 
doses of ivabradine (0.5, 5 or 15 mg/kg) we observed that ivabradine reduced heart rate 
in a dose-dependent manner (Fig. 5A). Subsequent studies of the effects of ivabradine 
on blood flow were carried out using 5 mg/kg ivabradine because this dose achieved an 
approximate 20% reduction in heart rate (Fig. 5A). We observed that ivabradine 
treatment significantly altered blood flow velocity in the ascending aorta by enhancing 
both the peak velocity and the average velocity over the cardiac cycle (Fig. 5B). 
Unsteady CFD simulations were then performed using time-varying waveforms from 
ivabradine-treated versus control animals as inlet boundary conditions and a single 
representative geometry. The kinetic changes in WSS magnitude were determined over 
the cardiac cycle for anatomically-distinct portions of the aortic arch.  At the inner 
curvature WSS displayed a transient peak followed by a rapid decline in magnitude (Fig. 
5C). By contrast, WSS magnitude declined less rapidly following systole in the outer 
curvature and was therefore higher in the outer compared to the inner curvature for most 
of the cardiac cycle (Fig. 5C). Consistent with this, mapping of time-averaged WSS onto 
the geometry of the aortic arch revealed higher values at the outer compared to the inner 
curvature (Fig. 6, left panels) as described16, 29, 30. Treatment with ivabradine generated a 
prolonged higher flow rate in the aorta after systole leading to a prolonged higher level 
WSS (Fig. 5C) and thus an enhanced time-averaged WSS at both the inner and outer 
curvatures (Fig. 6, compare left and right panels). These data linking reduced EC 
inflammatory activation with enhancement in time-averaged WSS in response to 
ivabradine are consistent with the hypothesis that ivabradine reduces inflammation in the 
aortic arch by enhancing the magnitude of WSS. 
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DISCUSSION 
Ivabradine treatment has been used successfully to treat coronary artery disease8, 9 and 
can also reduce atherosclerosis in experimental models11-13. In particular, ivabradine 
prevented renal and cerebral endothelial dysfunction in a mouse transgenic model of 
mild dyslipidaemia11 and prevented atherosclerotic lesion formation13 and improved 
erectile function12 in hypercholesterolemic ApoE-/- mice. The underlying mechanism has 
remained elusive because ivabradine-targets have not been identified in vascular cells 
and ivabradine did not influence plasma lipid levels11, 13. Given that ivabradine alters 
heart rate, stroke volume and coronary perfusion22, we tested the hypothesis that 
ivabradine may exert protective effects of arteries indirectly by altering hemodynamics 
which has been tightly linked to cardiovascular disease15-17. Our study demonstrated that 
ivabradine significantly altered flow in the murine aorta leading to enhanced WSS 
magnitude at both atheroprone and atheroprotected sites. Ivabradine induced protection 
from inflammation in the aorta (exposed to flow) but did not alter the inflammatory state 
of EC in conditions where flow was unaltered (either in vitro or in vivo), providing strong 
evidence that ivabradine functions indirectly via alteration of vascular mechanics. This is 
consistent with in vitro studies showing that VCAM-1 expression correlates inversely with 
shear stress magnitude31.  
 
Although it is well established that flow influences vascular function and disease, the 
relative contributions of WSS and mechanical wall stress remain uncertain. This is 
exemplified by Bolduc et al32 who compared the effects of heart rate reduction with 
ivabradine or metoprolol (E blocker) on arterial physiology and plaque development in 
hypercholesterolemic mice. Although metoprolol and ivabradine had similar effects on 
heart rate reduction, the influence of these compounds on vascular physiology varied 
according to anatomical location. In cerebral arteries and the aorta, ivabradine restored 
function and reduced plaque more effectively than metoprolol indicating that its 
protective effects include factors other than heart rate reduction per se. We propose that 
ivabradine confers additional vasculoprotective effects by enhancing stroke volume 
leading to elevated WSS. On the other hand, Bolduc et al32 found that ivabradine and 
metoprolol reduced carotid artery stiffness to a similar degree and suggested that this 
was due to reduced mechanical wall stress as a result of lowered heart rate. Collectively, 
these and our own observations suggest that ivabradine can modulate vascular function 
by altering mechanical stress as well as WSS and that the relative importance of these 
factors may vary according to anatomical site. 
 
The effects of ivabradine on cardiovascular hemodynamics and physiology partially 
mimic protection afforded by physical exercise which can also lower resting pulse rate 
and enhance stroke volume22. In clinical studies, exercise at 140-180% above resting 
heart rate enhanced peak blood flow velocity and increased WSS in the aorta33, 34. 
Bolduc et al32 compared the effects of ivabradine and physical exercise in 
hypercholesterolemic mice and found that while increased exercise and ivabradine both 
normalised cerebral artery function, only ivabradine reduced carotid artery stiffness. 
Further studies are required to determine whether the differential effects of these 
interventions on carotid and cerebral artery physiology are due to divergent effects on 
WSS and vascular mechanical stress. 
 
The numerical model used is consistent with models used in previous studies16, 29, 30. 
Since WSS is inversely proportional to the cubed radius of the vessel, vascular 
remodelling in response to ivabradine could have major effects on WSS. However, while 
ivabradine treatment significantly enhanced arterial blood flow velocity it did not modify 
the geometry of the aorta. Because of these considerations we compared fluid dynamics 
of ivabradine-treated and control mice using distinct inlet velocities (boundary conditions) 
applied to a single representative geometry. An important simplification of the numerical 
model was the use of a rigid geometry. In a detailed study of the murine aorta, Trachet et 
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al35 demonstrate that the inclusion of distensibility resulted in more realistic flow velocity 
waveforms using fluid structure interactions (FSI) compared to CFD using a rigid 
geometry. However, CFD and FSI gave similar predictions of WSS at proximal sites near 
the model inlet35. Because of this, we reason that the use of a rigid model in our 
simulations is justifiable because modelling is restricted to the aortic arch which is 
proximal to the flow inlet. Moreover, vascular distensibility may have relatively minor 
effects on WSS simulations in rodent vasculature since de Wilde demonstrated that CFD 
and FSI simulations were almost identical in murine carotid arteries36. Nevertheless, the 
use of a rigid geometry is a simplifying assumption that inevitably leads to a degree of 
error and prospective FSI studies should now be carried out to validate our observations 
using CFD. A second simplication concerns the physical properties of blood. Since blood 
is a highly concentrated suspension of red blood cells, it will exhibit non-Newtonian 
behaviour. However, since the level of shear rates in the murine aorta are relatively high, 
the assumption of Newtonian behaviour of blood is considered to be valid.  
 
Our observation that ivabradine reduces arterial expression of VCAM-1 is consistent with 
its ability to protect against atherogenesis11-13. The mechanism may involve eNOS, 
which was induced by ivabradine in our study and is known to inhibit inflammation via 
NO-dependent nitrosylation of pro-inflammatory signalling intermediaries and 
transcription factors21, 37. Notably, previous studies revealed that high WSS enhanced 
the expression of eNOS and reduced VCAM-118-21. Thus we hypothesize that ivabradine 
suppresses EC expression of VCAM-1 via WSS-dependent induction of eNOS. 
However, it is also plausible that the enhancement of WSS and/or modulation of 
vascular mechanical stress in response to ivabradine reduces inflammation via other 
mechanosensitive anti-inflammatory molecules including KLF2, Nrf2 and MKP-138, 39. 
 
In summary, we have identified a pharmacological approach using ivabradine to elevate 
WSS in the arterial tree. Altered WSS in response to ivabradine was accompanied by 
induction of a mechanosensitive protective gene (eNOS) and suppression of 
inflammatory VCAM-1. These observations demonstrate that ivabradine protects arteries 
by altering local mechanical conditions including increased WSS magnitude which 
triggers an anti-inflammatory response. In addition to providing an explanation for the 
protective effects of ivabradine, our study has broader significance by suggesting that 
interventions that alter blood flow (e.g. heart rate reduction by ivabradine or exercise) 
protect the vasculature, in part, by modulating local WSS. 
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Figure 1  Ivabradine treatment reduced heart rate in a murine model. LDLR-/- 
mice aged 9 weeks were treated using ivabradine (in drinking water) or remained 
untreated as a control (n=5 per group). After 1 week, both groups of mice were exposed 
to a high fat diet in the presence of absence of ivabradine treatment. Following 6 weeks, 
heart rate and blood pressure measurements were made and EC expression of specific 
proteins was determined by en face staining. (A) An overview of the experimental 
approach is shown. (B) Mean heart rates (upper panel), systolic (centre panel) and 
diastolic blood pressures (lower panel) +/- standard deviations are shown. Differences 
between means were analysed using an unpaired 6WXGHQW¶VW-test. n.s., non-significant. 
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Figure 2  Ivabradine reduced endothelial expression of VCAM-1 in the 
murine aorta. 
LDLR-/- mice aged 9 weeks were treated using ivabradine (in drinking water) or 
remained untreated as a control (n=5 per group). After 1 week, both groups of mice were 
exposed to a high fat diet in the presence or absence of ivabradine treatment. Following 
6 weeks, VCAM-1 expression levels in EC were assessed by en face staining of the 
inner and outer curvatures (red). EC were identified by co-staining with anti-CD31 
antibodies conjugated to FITC (green). Cell nuclei were identified using TOPRO-3 
(purple). Representative images and quantitation of VCAM-1 expression (mean +/- SEM) 
DUHVKRZQ6FDOHEDUȝP'LIIHUHQFHVEHWZHHQPHDQVZHUHDQDO\VHGXVLQJD-way 
ANOVA. 
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Figure 3   Ivabradine induced endothelial expression of eNOS in the murine 
aorta. LDLR-/- mice aged 9 weeks were treated using ivabradine (in drinking water) or 
remained untreated as a control prior to exposure to high fat diet for 6 weeks (n=7 
control group, n=8 ivabradine group). eNOS expression levels in EC were assessed by 
en face staining of the inner and outer curvatures (red). EC were identified by co-
staining with anti-CD31 antibodies conjugated to Alexa Fluor® 488 (green). Cell nuclei 
were identified using TOPRO-3 (purple). Representative images and quantitation of 
eNOS expression (mean +/- 6(0DUHVKRZQ6FDOHEDUȝP'LIIHUHQFHVEHWZHHQ
means were analysed using a 2-way ANOVA.  
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Figure 4  Ivabradine did not regulate inflammatory or protective gene 
expression in cultured endothelial cells. (A) HUVEC were exposed to low or high 
WSS for 72 h in the presence of varying concentrations of ivabradine (or in the absence 
of ivabradine as a control). Some cultures were subsequently exposed to TNFD (10 
ng/ml) from 68-72 h. The expression levels of specific transcripts were measured by 
qRT-PCR. Data were pooled from 3 independent experiments and mean values +/- 
standard errors are shown. Differences between means were tested using a 2-way 
ANOVA. Only significant differences are indicated. 
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Figure 5    Ivabradine altered hemodynamics in the murine aorta. (A) LDLR-/- mice 
aged 9 weeks were sedated using isofluorane prior to assessment of baseline heart 
rates by transthoracic echocardiography (untreated). (A) Mice were treated with 0.5, 5 or 
15 mg/kg ivabradine (i.v.) and heart rates were measured 15 min later. Data were pooled 
from 5 mice and mean values +/- standard deviations are presented. (B, C) LDLR-/- mice 
aged 9 weeks were sedated using isofluorane. Mice were then treated with ivabradine (5 
mg/kg; i.v.) and repeat measurements of aortic blood flow were made 15 min later 
(ivabradine). (B) Ultrasound data (left panels) were used to generate velocity waveforms 
(right panels). (C) The velocity distributions were used as boundary conditions for CFD 
assessment of the aorta. WSS was calculated over the cardiac cycle at outer and inner 
curvatures of the aorta in basal (control) and ivabradine-treated conditions. Data shown 
are representative of those generated in 5 independent experiments.  
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Figure 6   Ivabradine enhanced wall shear stress in the murine aorta. LDLR-/- mice 
aged 9 weeks (n=5) were sedated prior to the assessment of blood flow velocities in the 
aorta either prior to (control) or following administration of ivabradine (5 mg/kg; i.v.). The 
velocity distributions were used as boundary conditions for CFD assessment of the 
aorta. Time-averaged WSS were calculated and mapped onto the aortic geometry. 
Representative data from 5 independent experiments are shown in two orientations 
(inner curvature, upper panels; greater curvature, lower panels). Note that the 
brachiocephalic and left common carotid arteries are hidden in the upper panels due to 
the orientation of the vessel. 
 
 
 
 
